Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Country | IL |
| IPO Date | May 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman M.B.A., M.Sc. |
Contact Details
Address: Jerusalem BioPark Building Jerusalem, IL | |
| Website | https://www.scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | n/a |
| ISIN Number | US09073Q2049 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer & Director |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Liat Halpert | Head of Business Development & Sales |
| Merav Kamensky | Head of Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | SCHEDULE 13G | Filing |
| Nov 25, 2024 | 6-K | Filing |
| Nov 22, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 15, 2024 | 6-K | Filing |
| Sep 26, 2024 | 6-K | Filing |
| Sep 09, 2024 | 6-K | Filing |
| Aug 29, 2024 | 6-K | Filing |
| Aug 21, 2024 | 6-K | Filing |
| Aug 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |